Meglumine gadobenate 0.5mmol/ml solution for injection 20ml vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Meglumine gadobenate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 10 · 2001–2025
Showing the 50 most relevant studies, sorted by most relevant.
Qian Zhang, Anxin Wang, Qin Xu, et al.
JAMA Network Open, 2023
Meliana Borilli Pereira, B. Sydor, Karla Gabriela Memare, et al.
Nanomedicine, 2021
A. Ziegler, C. K. Freeman, C. Fogle, et al.
Equine veterinary journal, 2018
P. Machado, Camila da S. Ribeiro, Jaqueline França‐Costa, et al.
Tropical Medicine & International Health, 2018
R. N. R. Sampaio, Juliana Saboia Fontenele E Silva, Carmen Déa Ribeiro de Paula, et al.
Revista da Sociedade Brasileira de Medicina Tropical, 2019
D. Kasabalis, M. Chatzis, K. Apostolidis, et al.
Experimental parasitology, 2020
Dandan Zhang, Yi Wang, Zhihong Meng, et al.
Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022
Uzma Bashir, Moizza Tahir, Muhammad Irfan Anwar, et al.
Pakistan Journal of Medical Sciences, 2019
Quratulain Ejaz, Nighat Akbar, Sumyra Saleem
Journal of Pakistan Association of Dermatologists, 2019
Objective is an endemic disease. This study was done to compare the efficacy of intralesional meglumine antimoniate (MA) with combination of 50% trichloroacetic acid (TCA) and intralesional meglumine antimoniate in patients of cutaneous leishmaniasis (CL). Methods It was a randomized controlled trial conducted in department of dermatology, Military Hospital, Rawalpindi over six months i.e. 02-08-2016 to 01-02-2017. A total of 210 patients (105 in each group) were taken in this study. Group A received 50% TCA fortnightly with intralesional meglumine antimoniate and group B was treated with intralesional meglumine antimoniate alone. Results Efficacy was observed in 91 (86.7%) patients of group A and in 78 (74.3%) patients of group B (p=0.024). Conclusion Combination therapy with TCA 50% and intralesional MA accelerated the resolution of CL lesions with significant difference in complete resolution rate in comparison to the patients treated with intralesional MA alone.
Abstract licence: CC BY 4.0
Jamshida Iqbal Khattak, Ghafoor Ullah, Qamar uddin Khan
Journal of Pakistan Association of Dermatologists, 2021
Objective To compare the efficacy of combined parenteral Meglumine Antimoniate and oral Allopurinol with Meglumine Antimoniate alone in the treatment of Cutaneous Leishmaniasis. Study Design Randomized controlled trial. Place and duration of study Department of Dermatology, Combined Military Hospital, Peshawar from May 2016- Oct 2016. Methods A total of 112 patients presenting with Cutaneous leishmaniasis were included in the study and randomly allocated in two groups. In group I participants received combined therapy with oral allopurinol 15mg/kg/day and parenteral meglumine antimoniate 15mg/kg/day while group II participants received only meglumine antimoniate 15mg/kg/day. Follow up was done at 8th week and results were recorded. Results The mean age of the whole study sample was 27.4±4.6 years. In group I the efficacy was observed in 83.9% of patients compared to 73.2% in group II (p 0.167). Conclusion Our study concluded that the combination therapy (MA plus CL) is more effective in treating CL than isolation therapy with MA alone. More randomized controlled trials with larger sample sizes are highly recommended to draw more conclusive results and generate further evidence for uniform decision making in the treatment of CL.
Abstract licence: CC BY 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.